133 related articles for article (PubMed ID: 37909674)
1. Physiologically Based Pharmacokinetic Modeling of Nilotinib for Drug-Drug Interactions, Pediatric Patients, and Pregnancy and Lactation.
Liu XI; Leong R; Burckart GJ; Dallmann A
J Clin Pharmacol; 2024 Mar; 64(3):323-333. PubMed ID: 37909674
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Modeling to Supplement Nilotinib Pharmacokinetics and Confirm Dose Selection in Pediatric Patients.
Heimbach T; Lin W; Hourcade-Potelleret F; Tian X; Combes FP; Horvath N; He H
J Pharm Sci; 2019 Jun; 108(6):2191-2198. PubMed ID: 30721710
[TBL] [Abstract][Full Text] [Related]
3. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Ono C; Hsyu PH; Abbas R; Loi CM; Yamazaki S
Drug Metab Dispos; 2017 Apr; 45(4):390-398. PubMed ID: 28167538
[TBL] [Abstract][Full Text] [Related]
4. Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Prakash C; Fan B; Ke A; Le K; Yang H
Cancer Chemother Pharmacol; 2020 Nov; 86(5):619-632. PubMed ID: 32978634
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
6. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
Yun YE; Edginton AN
J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
[TBL] [Abstract][Full Text] [Related]
7. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.
Huang W; Nakano M; Sager J; Ragueneau-Majlessi I; Isoherranen N
Drug Metab Dispos; 2017 Nov; 45(11):1156-1165. PubMed ID: 28860113
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions.
Britz H; Hanke N; Taub ME; Wang T; Prasad B; Fernandez É; Stopfer P; Nock V; Lehr T
Pharm Res; 2020 Nov; 37(12):250. PubMed ID: 33237382
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19.
Liu XI; Dallmann A; Brooks K; Best BM; Clarke DF; Mirochnick M; van den Anker JN; Capparelli EV; Momper JD
CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):148-153. PubMed ID: 36479969
[TBL] [Abstract][Full Text] [Related]
11. Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients.
Kovar L; Weber A; Zemlin M; Kohl Y; Bals R; Meibohm B; Selzer D; Lehr T
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32977559
[TBL] [Abstract][Full Text] [Related]
12. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
Johnson TN; Rostami-Hodjegan A
Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
[TBL] [Abstract][Full Text] [Related]
13. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
14. A generic framework for the physiologically-based pharmacokinetic platform qualification of PK-Sim and its application to predicting cytochrome P450 3A4-mediated drug-drug interactions.
Frechen S; Solodenko J; Wendl T; Dallmann A; Ince I; Lehr T; Lippert J; Burghaus R
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):633-644. PubMed ID: 33946131
[TBL] [Abstract][Full Text] [Related]
15. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
[TBL] [Abstract][Full Text] [Related]
16. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
[TBL] [Abstract][Full Text] [Related]
17. Leveraging Physiologically Based Pharmacokinetic Modeling and Experimental Data to Guide Dosing Modification of CYP3A-Mediated Drug-Drug Interactions in the Pediatric Population.
Salerno SN; Carreño FO; Edginton AN; Cohen-Wolkowiez M; Gonzalez D
Drug Metab Dispos; 2021 Sep; 49(9):844-855. PubMed ID: 34154994
[TBL] [Abstract][Full Text] [Related]
18. Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug-Drug Interaction with Rifampin and Liver Impairment.
Gerner B; Scherf-Clavel O
Pharmaceutics; 2021 May; 13(6):. PubMed ID: 34067429
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Yamazaki S; Johnson TR; Smith BJ
Drug Metab Dispos; 2015 Oct; 43(10):1417-29. PubMed ID: 26180127
[TBL] [Abstract][Full Text] [Related]
20. Physiologically Based Pharmacokinetic Modeling of the Drug-Drug Interaction Between CYP3A4 Substrate Glasdegib and Moderate CYP3A4 Inducers in Lieu of a Clinical Study.
Callegari E; Tse S; Doran AC; Goosen TC; Shaik N
J Clin Pharmacol; 2024 Jan; 64(1):80-93. PubMed ID: 37731282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]